3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
17
Thoracic
6
Head & Neck
5
Gastrointestinal
5
Breast
5
Gynecologic
4
Lymphoid
3
Genitourinary
3
CNS
3
Sarcoma
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Leukemia
16
Lymphoma, Non-Hodgkin
9
Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma, Mantle-Cell
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma, Follicular
5
Burkitt Lymphoma
5
Recurrence
4
Neoplasms
4
Myelodysplastic Syndromes
4
Lymphoma, Large-Cell, Anaplastic
4
Congenital Abnormalities
4
Anemia, Refractory, with Excess of Blasts
4
Waldenstrom Macroglobulinemia
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Extranodal NK-T-Cell
3
Leukemia, Myelomonocytic, Juvenile
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoblastic Lymphadenopathy
3
Hematologic Neoplasms
3
Thrombocythemia, Essential
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
trametinib
2
dabrafenib
2
Palliative Care
2
Nivolumab
2
Methods
2
Ipilimumab
2
CTLA-4 Antigen
2
Biopsy
2
varlilumab
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
romidepsin
1
ripretinib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
peginterferon alfa-2a
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
fludarabine
1
erdafitinib
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Drug Therapy
×
Other hematologic neoplasm
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled